What the Research Says
Cranberry extract is widely recognized for its role in preventing urinary tract infections (UTIs), supported by robust evidence. A 2023 Cochrane review by Jepson et al., which analyzed 50 randomized controlled trials (RCTs) involving 8,857 participants, demonstrated that cranberry products reduce the risk of UTIs by 26% (RR 0.70, 95% CI 0.58-0.84), with particularly strong benefits for women with recurrent UTIs (RR 0.67). The review highlighted that products providing at least 36mg of proanthocyanidins (PACs) daily showed more consistent results, a threshold established by Howell et al. (2005) as the minimum dose to achieve significant anti-adhesion activity in urine bioassays.
Recent studies further support cranberry extract's effectiveness. Rondanelli et al. (2024) conducted a randomized controlled trial with 46 diabetic postmenopausal women, finding that daily cranberry extract supplementation significantly reduced UTI episodes compared to placebo over six months. However, not all studies have shown benefits across different populations. For instance, de Souza Gouveia Moreira et al. (2024) reported no significant effect of cranberry extract on inflammation or oxidative stress markers in a trial involving 30 chronic kidney disease patients.
Current best practice emphasizes the use of standardized extracts with quantified PAC content to ensure consistent efficacy, rather than relying on juice alone. These findings underscore cranberry extract's role as a valuable supplement for UTI prevention in susceptible populations.
